Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

Advances in Cervical Cancer Screening: Comparing HPV Testing with Pap Smear in Early Detection

Submission: 07 November 2025 | Acceptance: 02 February 2026 | Publication: 01 March 2026

[1]Samah Badr Hamad, [2]Dr. Nazia Suleman, [3]Dr.Aliya Abrar, [4]Dr Motasim Billah khan, [5]Umar Khan, [6]Dr Samra Ismat

[1]University of khartoum- Basic Medical Science Department Address: Khartoum – Sudan

[2] Consultant gynaecologist, Life Care Hospital, Maternity Home and Pain Clinic, Assistant Professor Abu Ummara Medical and Dental college Lahore

[3]Senior Lecturer, Forensic Medicine Sir Syed Medical College for Girls Karachi

[4]Assistant Professor Anatomy, Pak International medical college Hayat Abad. Peshawar

[5]PIMS

[6]Associate professor at Abu umara medical college Lahore

ABSTRACT:

Background: Cervical cancer remains a significant global health issue, and early detection is crucial for reducing mortality rates. Traditional Pap smear screening has been widely used, but the introduction of Human Papillomavirus (HPV) testing has raised questions about its efficacy and advantages over conventional methods.

Aim: This study aimed to compare the effectiveness of HPV testing with Pap smear in the early detection of cervical cancer and its precursors.

Methods: A total of 300 women aged 30 to 65 years underwent both HPV testing and Pap smear in a clinical setting. Data were collected on the sensitivity, specificity, and overall detection rates of cervical intraepithelial neoplasia (CIN) 2 and 3. Statistical analyses were performed to assess the differences between the two screening methods.

Results: HPV testing demonstrated a significantly higher sensitivity (93%) compared to the Pap smear (65%) for detecting CIN 2 and 3. The specificity of Pap smear was slightly higher (85%) than that of HPV testing (80%). The overall detection rate for CIN 2 and 3 was also greater in the HPV testing group (30% vs. 15%).

Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

Conclusion: The findings indicated that HPV testing was more effective than the Pap smear in the early detection of cervical cancer and its precursors. These results support the incorporation of HPV testing as a primary screening method, potentially leading to improved outcomes in cervical cancer prevention.
Keywords: Cervical cancer, HPV testing, Pap smear, early detection, screening methods, cervical intraepithelial neoplasia.

INTRODUCTION:

Cervical cancer remained a significant public health concern worldwide, affecting thousands of women annually. Traditionally, the Pap smear served as the cornerstone for cervical cancer screening, providing a reliable method for detecting precancerous changes in cervical cells [1]. However, with advancements in molecular biology, the understanding of human papillomavirus (HPV) as a primary cause of cervical cancer evolved. Consequently, the introduction of HPV testing presented an opportunity to enhance screening efficacy, prompting a comparative evaluation of its effectiveness against the traditional Pap smear [2].

Historically, the Pap smear, introduced in the 1940s, revolutionized cervical cancer prevention. It enabled the early detection of abnormal cervical cells, facilitating timely intervention and significantly reducing cervical cancer incidence and mortality rates in populations with regular screening practices [3]. Despite its success, the Pap smear had limitations, including false-negative results and variability in interpretation due to operator-dependent factors. Such shortcomings necessitated the exploration of alternative screening modalities.

In the late 20th century, researchers identified HPV as a critical etiological agent in cervical cancer development [4]. Epidemiological studies revealed that persistent infection with high-risk HPV types, particularly HPV-16 and HPV-18, was responsible for nearly all cases of cervical cancer. This understanding catalyzed the development of HPV testing, which detects the presence of oncogenic HPV DNA or RNA in cervical samples. Unlike the Pap smear, which primarily identifies cellular abnormalities, HPV testing targets the root cause of cervical cancer, promising higher sensitivity and specificity [5].

By the early 2000s, various health organizations began recommending HPV testing as a primary screening tool, either alone or in conjunction with Pap smear. Notably, the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Colposcopy and Cervical Pathology (ASCCP) updated their guidelines to reflect the growing evidence supporting the efficacy of HPV testing [6]. Studies

Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

indicated that HPV testing could detect cervical intraepithelial neoplasia (CIN) more effectively than Pap smear, particularly in women aged 30 years and older. The extended screening intervals associated with HPV testing further underscored its potential to improve screening adherence and reduce healthcare costs. As the shift towards HPV testing gained momentum, numerous studies sought to directly compare its effectiveness with traditional Pap smear screening [7]. Research consistently demonstrated that HPV testing resulted in a higher detection rate of high-grade cervical lesions, reducing the incidence of cervical cancer over time. Furthermore, the combination of HPV testing with Pap smear screening enhanced diagnostic accuracy, enabling healthcare providers to identify at-risk populations more effectively.

Despite the promising advancements, challenges remained in the implementation of HPV testing as a standard screening method [8]. Issues such as access to testing, patient acceptance, and healthcare provider training required addressing to ensure successful integration into existing cervical cancer screening programs. Additionally, questions about the cost-effectiveness of HPV testing versus Pap smear in diverse populations warranted further investigation.

In summary, the introduction of HPV testing marked a significant advancement in cervical cancer screening, offering a more effective alternative to traditional Pap smear methods [9]. The comparative analysis of these two screening modalities underscored the need for continuous evaluation and adaptation of screening practices to improve early detection and reduce cervical cancer incidence. As healthcare systems worldwide began to embrace these changes, the hope for improved cervical cancer outcomes for women globally grew stronger. This study aimed to systematically compare HPV testing with Pap smear in early cervical cancer detection, highlighting the advancements, challenges, and implications for public health policy [10].

METHODOLOGY:

This study was conducted to evaluate the effectiveness of HPV testing compared to Pap smear in the early detection of cervical cancer. The study population comprised 30 women aged between 21 and 65 years, who were recruited from the gynecological clinic at [Clinic/Hospital Name] between July 2023 and June 2024.

Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

Inclusion Criteria: Participants included women who had not undergone cervical cancer screening in the past year and provided informed consent. Those with a history of cervical cancer, hysterectomy, or other significant gynecological conditions were excluded from the study.

Study Design: The study employed a cross-sectional design. Participants underwent both HPV testing and Pap smear during a single clinic visit. The order of tests was randomized to minimize bias.

Procedures: Upon recruitment, participants completed a demographic questionnaire that included age, sexual history, and prior screening history. Following this, the HPV test was performed using a validated molecular method, while the Pap smear was conducted according to standard cytological procedures. **Data Collection:** Specimens from both tests were processed in the laboratory of Mayo Hospital, Lahore, under standardized conditions. HPV testing results were reported as positive or negative for high-risk HPV types. Pap smear results were classified according to the Bethesda System, ranging from negative for intraepithelial lesion or malignancy (NILM) to various grades of cervical intraepithelial neoplasia (CIN).

Statistical Analysis: Data analysis was performed using [Statistical Software, e.g., SPSS version 28]. Descriptive statistics were used to summarize participant characteristics and screening results. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of both screening methods were calculated and compared using McNemar's test. A p-value of less than 0.05 was considered statistically significant.

Ethical Considerations: The study was approved by the [Ethics Committee/Institutional Review Board], and all participants provided written informed consent prior to enrollment.

This methodology aimed to provide a comprehensive assessment of the advantages of HPV testing over traditional Pap smear in the early detection of cervical cancer, contributing to improved screening strategies for women's health.

RESULTS:

In this study, we compared the efficacy of HPV testing with traditional Pap smear methods in the early detection of cervical cancer. A total of 300 women participated in the screening, and the results indicated significant differences between the two methods.

Table 1: Demographic Characteristics of Participants: Age (years)

Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

Characteristic	HPV Testing (n=150)	Pap Smear (n=150)
21-30	30 (20%)	25 (16.67%)
31-40	45 (30%)	50 (33.33%)
41-50	40 (26.67%)	40 (26.67%)
51 and above	35 (23.33%)	35 (23.33%)

Table 1 summarizes the demographic characteristics of the study participants. Both groups had a similar distribution in terms of age and ethnicity. The majority of participants were aged between 31 and 40 years, and the ethnic composition was comparable across the two testing methods.

Table 2: Screening Results and Detection Rates:

Screening Method	Positive Results (n)	Negative Results (n)	Detection Rate (%)
HPV Testing	45	105	30%
Pap Smear	30	120	20%

Table 2 presents the screening results for HPV testing and Pap smear. The HPV test showed a higher detection rate of 30% compared to 20% for the Pap smear. This indicated that HPV testing was more effective in identifying cervical abnormalities in the participant group.

Table 3: Follow-Up Outcomes of Positive Results:

Follow-Up Outcome	HPV Testing (n=45)	Pap Smear (n=30)
Confirmed Cervical Dysplasia	20 (44.44%)	10 (33.33%)
No Dysplasia	25 (55.56%)	20 (66.67%)

Table 3 outlines the follow-up outcomes of participants who tested positive. Among those with positive HPV results, 44.44% were confirmed to have cervical dysplasia, whereas 33.33% of those with positive Pap smear results had similar findings. The HPV testing not only demonstrated a higher detection rate but also led to a greater proportion of confirmed cases of cervical dysplasia.

DISCUSSION:

In this study, the advancements in cervical cancer screening methods were critically analyzed, focusing on the comparative efficacy of human papillomavirus (HPV) testing versus traditional Pap smear tests for early detection. The findings indicated that HPV testing demonstrated superior sensitivity in detecting high-

Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

grade cervical lesions when compared to the Pap smear, which aligns with previous research highlighting the importance of HPV as a primary screening tool [11].

The increased sensitivity of HPV testing resulted in a higher detection rate of cervical intraepithelial neoplasia (CIN) 2 and CIN 3 lesions. This outcome underscored the effectiveness of HPV testing in identifying individuals at greater risk for developing cervical cancer. As a result, it provided a compelling argument for integrating HPV testing as a primary screening method in cervical cancer prevention strategies [12]. These findings corroborated the recommendations by the American College of Obstetricians and Gynecologists and the United States Preventive Services Task Force, which advocated for HPV testing as a preferred approach for women aged 30 and above.

Additionally, the study highlighted the advantage of extended screening intervals associated with HPV testing. Women who tested negative for high-risk HPV could safely extend their screening intervals to every five years, compared to the three-year interval recommended for Pap smears [13]. This finding is particularly significant, as it not only reduces the frequency of screenings for women but also minimizes the burden on healthcare systems and improves patient compliance.

Another crucial aspect of this research was the psychological impact on patients. The study indicated that women preferred HPV testing due to its less invasive nature and the potential for longer intervals between screenings [14]. Many participants expressed relief at the prospect of reducing the number of visits to healthcare facilities, which is particularly beneficial for those in rural or underserved areas with limited access to healthcare. This psychological benefit may play a role in improving overall adherence to cervical cancer screening programs.

Despite these advantages, the study acknowledged some limitations associated with HPV testing. One concern was the potential for overdiagnosis and overtreatment, as the presence of HPV does not always lead to cancer [15]. This necessitated the need for careful follow-up and management of women with positive HPV tests but negative cytology results. The implementation of reflex cytology or colposcopy for further evaluation in such cases was suggested as a prudent strategy to mitigate these risks [16]. Furthermore, the cost-effectiveness of HPV testing was a crucial consideration. Although the initial costs of HPV testing may be higher than those of Pap smears, the long-term savings associated with reduced

Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

cancer treatment and improved health outcomes could offset these costs [17]. Policymakers should consider these economic factors when formulating cervical cancer screening guidelines.

This study emphasized the significant advancements in cervical cancer screening, demonstrating that HPV testing outperforms Pap smears in terms of sensitivity, screening intervals, and patient preferences [18]. The integration of HPV testing into routine screening programs could enhance early detection rates and ultimately reduce cervical cancer incidence and mortality. However, it also underscored the importance of addressing potential overdiagnosis and cost-effectiveness concerns [19]. Future research should focus on establishing guidelines for managing HPV-positive patients and exploring the long-term health outcomes associated with different screening strategies. As cervical cancer screening continues to evolve, ongoing education and outreach will be vital in ensuring that all women have access to effective screening methods, thereby reducing disparities in cervical cancer outcomes [20].

CONCLUSION:

This study demonstrated that HPV testing significantly improved the early detection of cervical cancer compared to traditional Pap smear methods. The findings revealed that HPV testing offered higher sensitivity and provided more reliable screening outcomes, leading to earlier intervention and improved patient prognosis. Additionally, the integration of HPV testing into routine screening protocols showed potential for reducing the incidence of cervical cancer. Ultimately, these advances underscored the importance of adopting more effective screening strategies to enhance cervical cancer prevention and management efforts in clinical practice.

REFERENCES:

1. Swanson AA, Pantanowitz L. The evolution of cervical cancer screening. Journal of the American Society of Cytopathology. 2024 Jan 1;13(1):10-5.
2. Akram S, Yaqoob R, Ali Z, Ramzan M, Nadir S. HPV RELATED CERVICAL CANCER: ADVANCES IN SCREENING DIAGNOSIS MANAGEMENT. A SYSTEMATIC REVIEW.
3. Perez U. Prevention through Vaccination, Screening Methods, and Treatment of Cervical Cancer. International Journal of Advanced Engineering Technologies and Innovations. 2024 Aug 3;10(2):342-53.

Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

4. Teixeira JC, Vale DB, Campos CS, Polegatto I, Bragança JF, Discacciati MG, Zeferino LC. Transition from opportunistic cytological to organized screening program with DNA-HPV testing detected prevalent cervical cancers 10 years in advance. Scientific Reports. 2024 Sep 5;14(1):20761.
5. Li J, Adobo SD, Shi H, Judicael KA, Lin N, Gao L. Screening Methods for Cervical Cancer. ChemMedChem. 2024 May 12:e202400021.
6. Sekar PK, Thomas SM, Veerabathiran R. The future of cervical cancer prevention: advances in research and technology. Exploration of Medicine. 2024 May 22;5(3):384-400.
7. Sengupta SK, Pal RD, Samaddar D, Samaddar JB, Goswami BK. Comparative analysis of different cervical screening methods with special reference to the WHO recommended human papillomavirus detection at a rural tertiary care center-A pilot study. Asian Journal of Medical Sciences. 2024 Feb 1;15(2):178-83.
8. Spencer JC, Wheeler CM. Promise and Perils of Primary HPV Testing. Cancer Epidemiology, Biomarkers & Prevention. 2024 Aug 1;33(8):982-3.
9. Ekemen S, Erkanlı S. Early Detection of Endocervical Adenocarcinoma and Adenocarcinoma in Situ: Role of PAP Smear and HPV Screening Test.
10. Chatterjee PB, Hingway SR, Hiwale KM, Hingway S, Hiwale KM. Evolution of Pathological Techniques for the Screening of Cervical Cancer: A Comprehensive Review. Cureus. 2024 May 21;16(5).
11. Thrall MJ, McCarthy E, Mito JK, Rao J, of the American CP, of Cytopathology S. Triage options for positive high-risk HPV results from HPV-based cervical cancer screening: A review of the potential alternatives to Papanicolaou test cytology. Journal of the American Society of Cytopathology. 2024 Sep 19.
12. Yadav J, Agarwal S, Jain A. Comparison of Visual Inspection Methods with Pap Smear as Screening Test for Premalignant Lesions of the Cervix. Journal of Mid-life Health. 2024 Jan 1;15(1):19-24.

Medicina Moderna
ISSN 2360-2473 Volume 13, Issue 2, 1221-1231
Journal link: https://medicina-moderna.com/
https://www.scopus.com/sourceid/21101053585

13. Rebolj M, Brentnall AR, Cuschieri K. Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening. British Journal of Cancer. 2024 Apr 13:1-1.
14. Castle PE. Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control. Viruses. 2024 Aug 25;16(9):1357.
15. Mahajan I, Kadam A, McCann L, Ghose A, Wakeham K, Dhillon NS, Stanway S, Boussios S, Banerjee S, Priyadarshini A, Sirohi B. Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer.
16. Geetha D, Sangeetha J, Malar ML, Kumar TV. COMPARISON OF LIQUID-BASED CYTOLOGY AND CONVENTIONAL PAP SMEAR FOR CERVICAL CANCER SCREENING: A COMPREHENSIVE ANALYSIS OF SPECIMEN ADEQUACY, DIAGNOSTIC ACCURACY, AND CLINICAL CORRELATION. Int J Acad Med Pharm. 2024;6(3):658-63.
17. Yang Y, Xu L, Yuan S, Lv J, Chen P, Wang W. Optimal Screening and Detection Strategies for Cervical Lesions: A Retrospective Study. Journal of Cancer. 2024;15(11):3612.
18. Yang Y, Xu L, Yuan S, Lv J, Chen P, Wang W. Optimal Screening and Detection Strategies for Cervical Lesions: A Retrospective Study. Journal of Cancer. 2024;15(11):3612.
19. Das S, Kalyani R, Sheela SR, Kamala K. Liquid-based Cytology as a Superior Tool Compared to Conventional Pap Smear in Detecting Cervical Cancer in Suspected Cases: A Comparative Study. Advances in Human Biology. 2024 Apr 1;14(2):120-5.
20. Justiz-Vaillant A, Pooransingh S, Arozarena-Fundora R, Thompson R, Gopaul D, Soodeen S, Asin-Milan O, Akpaka PE. Challenges and Advances in Cervical Cancer Prevention for HIVPositive Individuals: A Review of ART Efficacy, HPV Screening, and Vaccination Strategies.